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SUMMARY Acne is the most common skin disease, with a relative prevalence of 
85%-100% among young individuals. It affects the cosmetic appearance of the 
patients provoking severe distress. A number of different topical treatments have 
been used for the treatment of acne. In this study, we investigated the efficacy and 
safety of the topical treatment with 5% benzoyl peroxide and 3% erythromycin gel 
in patients with papulopustular acne. One hundred and ninety-one patients with 
inflammatory acne completed the study. The patients included 54 males and 137 
females, mean age 22.3±8.1 years. Topical gel was applied on the face once daily for 
3 months. The mean number of non-inflammatory and inflammatory lesions after 
3 months of therapy decreased significantly with respect to baseline, with a mean 
percentage reduction of the non-inflammatory and inflammatory lesions by 42.2% 
and 57.5%, respectively. In conclusion, topical 5% benzoyl peroxide and erythromy-
cin 3% as monotherapy is efficient for the treatment of papulopustular acne.
KEY woRdS: papulopustular acne, treatment, topical treatment, 5% benzoyl per-
oxide gel, erythromycin 3% gel, antibiotics
InTRodUCTIon
Acne is the most common skin disease with a 
relative prevalence of 85%-100% among young indi-
viduals (1). It is considered a disorder of the piloseba-
ceous follicle with most common features being an 
increased sebum production, follicular keratinization, 
localized inflammation and colonization by Propioni-
bacterium acnes and Staphylococcus epidermidis (2,3). 
There are various types of acne, depending on the 
severity of the condition and acne vulgaris is consid-
ered the most frequent one. It affects the cosmetic 
appearance of the patients, provoking severe distress. 
Several different topical therapies have been used for 
the treatment of acne. Although safe, a dramatic in-
crease in bacterial resistance over the past 20 years 
has been seen, probably as a result of the use of topi-
cal antibiotics (4,5), leading to combination products 
of different topical treatments.   
The combination of 5% benzoyl peroxide-erythro-
mycin 3% (gel Erybenz®, Verisfield, Athens, Greece) has 
been approved and introduced in the Hellenic market 
since March 2008. The present study aimed to provide 
additional evidence for the efficacy of 5% benzoyl 
peroxide-erythromycin 3% gel used as monotherapy 
for the treatment of papulopustular acne.
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MATERIAlS And METhodS
Patient selection
The study was conducted from October 2009 to 
April 2010 in Athens and Tripolis, Greece. The individ-
uals included in this study were 55 outpatients that 
were examined in the Dermatological Department of 
the Veterans Administration Hospital, 27 outpatients 
examined in the Dermatological Department of the 
Attikon General University Hospital and 123 patients 
examined in private practices. The study protocol was 
approved by the Ethics Committee of the participat-
ing hospitals and the patients signed informed con-
sent forms.  
The eligibility criteria were mild to moderate 
papulopustular acne (grade II-III by the Pillsbury clas-
sification system) (6), with inflammatory lesions (>10 
pustules and/or papules) and non-inflammatory fea-
tures (>10 comedones) on the facial area.
The criteria for patient exclusion were as follows: 
(a) pregnant and breast feeding women; (b) children 
under the age of 11 years; (c) severe cases of acne 
(presence of nodules and cysts); (d) patients on sys-
temic treatment with isotretinoin, hormones or anti-
biotics for acne or other condition; (e) patients receiv-
ing topical anti-acne treatments (benzoyl peroxide, 
retinoids, azelaic acid) or topical corticosteroids for 
the last month; (f ) patients taking drugs capable of 
producing acneiform eruptions such as oral or local 
steroids, vitamin B12, anticonvulsive drugs; and (g) 
patients with facial dermatoses that could interfere 
with the evaluation of the study.
Two hundred and five patients with inflammatory 
acne (comedones, papules and/or pustules) were 
originally recruited. Ten patients were lost to follow-
up or voluntary withdrawal and four patients discon-
tinued the treatment, thus 191 individuals completed 
the study. Our statistical analysis and evaluation of 
the combination of 5% benzoyl peroxide-erythromy-
cin 3% efficacy was based on the data collected from 
191 patients who completed the study. 
Of these patients, 54 were males and 137 females, 
mean age 17±3.2 and 24.3±8.5 years, respectively 
(Table 1). Sixty-eight patients had mild acne and 123 
had moderate acne at baseline (Table 1). 
Topical therapy
The combination of 5% benzoyl peroxide-eryth-
romycin 3% was applied once daily as monotherapy. 
The dosage scheme included initially a face-cleans-
ing step using the same non-medicated soap (active 
foam, Frezyderm®, Athens, Greece) and the applica-
tion of the topical gel 5% benzoyl peroxide-erythro-
mycin 3% as a thin layer on the face including affect-
ed and non-affected areas. The topical agent was ap-
plied only on the face once daily for 3 months. In ad-
dition, patients were advised to avoid the use of the 
topical agent with dark clothing and were allowed to 
use non-comedogenic products, for example, make 
ups throughout the study.
Patient baseline characteristics
A total of 191 patients with papulopustular acne 
completed the study. The majority of patients were 
female (n=137, 71.7% of the sample), while the mean 
age of the sample (± standard deviation) was 22.3±8.1 
years (Table 1). Age differed between the two gen-
ders (T-test statistic p<0.001). On the average, men 
were seven years younger than women (mean age, 
17.2±3.2 and 24.3±8.5 years, respectively).
The mean number of non-inflammatory lesions 
at baseline was 28.8±11.5, while the mean number 
of inflammatory lesions was 15.8±5.5 (Table 2). These 
Baseline number of non-inflammatory lesions
Gender Age (years) Total
Female Male <=22 >22
Mean 27.7 31.5 30.0 26.9 28.8
Std Deviation 10.6 13.2 12.0 10.4 11.5
N 137 54 115 76 191
Baseline number of inflammatory lesions 
Mean 16.8 13.3 15.7 16.0 15.8
Std Deviation 5.8 3.7 5.4 5.7 5.5
N 137 54 115 76 191
N %






Table 1. Gender and age of the patients. Base: All 
patients (Ν=191)
Table 2. Mean baseline number of lesions, by gender and age. Base: All patients (Ν=191)
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findings were statistically significantly different be-
tween males and females, as shown in Table 2 (non-
inflammatory lesions: multiple linear regression t-sta-
tistic p=0.040, T-test statistic p=0.040; inflammatory 
lesions: multiple linear regression t-statistic p<0.001, 
T-test statistic p<0.001). More specifically, the num-
ber of non-inflammatory lesions was greater in men, 
while the number of inflammatory lesions was great-
er in women (Table 2).
Assessment of efficacy
The primary outcome utilized for efficacy assess-
ment was the overall mean number of inflammatory 
and non-inflammatory lesions, expressed as percent-
age decline from the baseline (week 0-week 12). Each 
participant’s lesions were counted at the beginning 
(week 0-baseline) and at the end of treatment (week 
12).
The secondary outcome included patient satis-
faction, i.e. the proportion (percentage) of patients 
that reported a slight to moderate improvement, sig-
nificant improvement, or complete cure of their facial 
acne on a 4-point scale. Each patient was scored on 
a 0-3 scale (0 = worse or no improvement; 1 = slight 
to moderate improvement; 2 = significant improve-
ment; and 3 = complete cure).
Any features of local irritation and adverse events 
identified from the start of the study medication were 
recorded. 
Statistics
Statistical analysis of the baseline characteristics 
as well as the findings after treatment was carried out 
using the following methods:
1  T-test examined the association of gender with 
age.
2 Multiple linear regression technique (method = 
stepwise/forward) tested the statistical relation be-
tween the baseline number of inflammatory and 
non-inflammatory lesions (dependent variables) 
and the variables of age and gender (independent 
variables).
3  Paired sample t-test compared the baseline num-
ber of inflammatory and non-inflammatory lesions 
with the respective values after treatment.
4  The same test compared the mean percentage 
reduction of inflammatory lesions from baseline 
([baseline number of lesions – number of lesions 
after treatment] X100/baseline number of lesions) 
with the respective reduction of the non-inflam-
matory ones.
5  Multiple linear regression technique (method = 
stepwise/forward) tested the statistical relation of 
the percentage reduction of inflammatory lesions 
(dependent variable) with the variables of age and 
gender (independent variables).
6  The same technique tested the statistical relation 
between the percentage reduction of non-inflam-
matory lesions (dependent variable) and the vari-
ables of age and gender (independent variables).
Independent variables: Tests:
Gender T-test
Age Pearson correlation coefficient
Percentage reduction of the inflammatory and non-inflammatory lesions Spearman’s correlation coefficient
Figure 1. Mean number of non-inflammatory le-
sions before and after treatment. Base: all patients 
(Ν=191).
Figure 2. Mean number of inflammatory lesions be-
fore and after treatment. Base: all patients (Ν=191).

















Rallis et al. Acta Dermatovenerol Croat
Topical 5% benzoyl peroxide and 3% erythromycin gel  2013;21(3):160-167




















Table 3. Statistical parameters for findings analysis
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7  Finally, the same technique was applied to test the 
relation of patient satisfaction with treatment (de-
pendent variable) with the variables of age, gender 
and percentage reduction of inflammatory and 
non-inflammatory lesions (independent variables) 
(Table 3).
8  All findings of the linear regression techniques 
were cross-validated using the following univari-
ate tests
A finding was considered significant if it was 
traced by both regression and univariate techniques.
RESUlTS
Reduction of inflammatory and non-in-
flammatory lesions
Upon completion of the study, the mean number of 
non-inflammatory lesions decreased from 28.8±11.5 
at baseline to 16.5±8.1 at the last visit (mean decrease 
= 12.3±7.7) (Fig. 1), while the mean number of inflam-
matory lesions decreased from 15.8±5.5 at baseline 
to 6.7±3.7 at the last visit (mean decrease = 9.1±4.5), 
as shown in Figure 2. These findings were statistically 
significant (paired sample T-test, p<0.001 both).
The mean percentage reduction of inflammatory 
lesions from baseline ([baseline number of lesions 
– number of lesions after treatment] X100/baseline 
number of lesions) was greater than the respective 
reduction of non-inflammatory ones (paired sample 
t-test, p<0.001). More specifically, the mean percent-
age reduction of non-inflammatory lesions from 
baseline was 42.2±18.7%, while the respective per-
centage for inflammatory lesions was 57.5±21.0% 
(Table 4, Fig. 3).  
The percentage reduction of inflammatory and 
non-inflammatory lesions was greater in men than 
in women (non-inflammatory lesions: multiple linear 
regression t-statistic p<0.001, T-test statistic p-value 
Non-inflammatory lesions
Age (years) Gender Total
<=22 >22 Female Male
Mean 45.1 37.9 38.9 50.7 42.2
Std Deviation 18.0 19.0 18.2 17.4 18.7
N 115 76 137 54 191
Inflammatory lesions
Mean 60.4 53.0 53.3 67.9 57.5
Std Deviation 20.5 21.1 20.6 18.3 21.0
N 115 76 137 54 191
Table 4. Number of lesions: Percentage reduction from baseline, by gender and age. Base: All patients (Ν=191)
Figure 3. Number of lesions: Percentage (%) reduction from baseline.  


























Figure 3. Number of lesions: percentage (%) reduc-
tion from baseline. Base: all patients (Ν=191).
Figure 4. (a) Acne with inflammatory and non-inflam-
matory features before treatment initiation (baseline) 
with the topical agent; (b) Acne after topical treat-
ment (week 12). Significant clinical improvement.
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<0.001; inflammatory lesions: multiple linear regres-
sion t-statistic p<0.001, T-test statistic p<0.001).
The mean percentage reduction of non-inflamma-
tory lesions was 50.7±17.4% in men and 38.9±18.2% 
in women, while the mean percentage reduction of 
inflammatory lesions was 67.9±18.3% in men and 
53.3±20.6% in women (Table 4, Figs. 4a, b and 5a, b).
Patient satisfaction score
Patient satisfaction with treatment correlated 
positively with the percentage reduction of inflam-
matory lesions from baseline (multiple linear regres-
sion t-statistic p<0.001/Spearman’s rho correlation 
coefficient = 0.606, p<0.001) (Fig. 6).
Adverse events
Four patients discontinued their treatment. In 
three patients, two females and one male, the 5% 
benzoyl peroxide-erythromycin 3% preparation in-
duced dermatitis that subsided without topical cor-
ticosteroids upon cessation of topical medication. 
The fourth patient, a female, withdrew from the treat-
ment because of poor results after only one month 
of application. Another patient, a female, mentioned 
clothing discoloration that did not lead to treatment 
discontinuation.
No serious adverse events were observed. No pho-
tosensitivity, acne aggravation or hypomelanosis in 
the area of application were noted. The four patients 
that discontinued treatment belonged to those that 
did not respond sufficiently to 5% benzoyl peroxide-
erythromycin 3% topical preparation (Fig. 6). 
In general, the topical agent was well tolerated 
with limited and transient side effects, usually seen 
at the beginning of treatment. The majority of the ad-
verse effects recorded were mild to moderate and did 
not require treatment discontinuation.  
dISCUSSIon
Clinical presentation of acne varies depending on 
the condition severity (7,8). Acne vulgaris is common 
in teenagers and usually resolves by the age of 20; 
only a few individuals require treatment in their 30s 
or 40s. The areas of the skin that are primarily affected 
include the face, shoulders, upper chest and back (9). 
The treatment of acne aims to reduce bacterial colo-
nization of the pilosebaceous follicle, reduce the rate 
of sebum production, reduce inflammation, and re-
move the keratinized layer that blocks the follicles. 
Systemic acne therapy includes the use of oral an-
tibiotics, retinoids and oral contraceptives, depend-
ing on the disease severity. In the class of retinoids, 
oral isotretinoin is the treatment of choice for severe 
acne (10). Since isotretinoin is a teratogenic agent, 
pregnancy must be avoided and contraception coun-
seling is mandatory. It may also produce additional 
problems and patients experiencing its side effects 
should have their treatment adjusted according to 
therapy response (11).  
Oral antibiotics include oxytetracycline, eryth-
romycin, minocycline, doxycycline, lymecycline or 
trimethoprim (1). Oral antibiotic therapy may be as-
sociated with gastrointestinal disturbance, vaginal 
candidiasis, pseudomembranous colitis, and in case 
of tetracyclines vestibular disturbances and photo-
toxic effects. Furthermore, oxytetracycline may com-
promise patient compliance to therapy, as it requires 
no concomitant administration with food and milk in 
order to increase absorption (12). Oral administration 
Figure 5. (a) Acne with inflammatory and non-inflammatory features before treatment (week 0); (b) Acne with 
inflammatory and non-inflammatory features after treatment with 5% benzoyl peroxide-erythromycin 3% 
(week 12).
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of erythromycin has been associated with increased 
systemic adverse effects and resistance of P. acnes 
strains (9). On the other hand, doxycycline and mi-
nocycline are considered as second-line treatments, 
and trimethoprim as a third-line antibiotic option in 
patients who have failed to respond to alternative an-
tibiotic treatment (13).
The advent of topical therapy has provided al-
ternative treatment schemes in the management of 
acne. It is a safe substitute administered when: (i) acne 
is mild; (ii) systemic treatment is contraindicated; and 
(iii) to reduce the adverse effects of systemic antibiot-
ics and retinoids and offer better patient compliance. 
Topical treatments include topical retinoids, ben-
zoyl peroxide alone or in combination with an anti-
biotic, azelaic acid and topical antibiotics (14). How-
ever, one of the major setbacks in the use of topical 
antibiotics has been the dramatic increase in bacte-
rial resistance over the past 20 years (4,5). Therefore, 
combination therapies with topical antibiotics (e.g., 
with benzoyl peroxide, either alternating or as fixed 
combinations, or alternating with azelaic acid) are 
now preferred due to the reduction in P. acnes resis-
tance, counteraction of new resistant strains and re-
duction in the risk of resistant Staphylococcus aureus 
colonization (4,15).
In this 12-week study, the primary efficacy results 
indicated that topical treatment of acne with 5% 
benzoyl peroxide and 3% erythromycin gel as mono-
therapy was associated with a significant reduction 
of inflammatory and non-inflammatory acne lesions, 
as shown by their mean percentage reductions from 
baseline by 42.2% and 57.5% for non-inflammatory 
and inflammatory lesions, respectively (Figs. 3, 4a, b 
and 5a, b). These findings are in agreement with pre-
viously published data obtained from efficacy and 
comparative studies using the combination of ben-
zoyl peroxide and erythromycin (16-19). On the other 
hand, a mean percent reduction of acne lesions from 
baseline has been reported in randomized controlled 
studies with other topical acne treatments: for inflam-
matory lesions 29% to 40% and for non-inflammatory 
lesions 24% to 40% (20,21). 
In our study, patient adherence to treatment was 
based on their history of treatment application. In 
terms of safety, no serious adverse effects were ob-
served. 
In terms of acne characteristics recorded, includ-
ing non-inflammatory (comedones) and inflamma-
tory features (papules and pustules), the combina-
tion agent (5%) benzoyl peroxide-erythromycin (3%) 
resulted in a significant reduction in the number 
of both types of lesions over the 12-week study, as 
shown in Figures 1 and 2, with a mean decrease in 
the number of non-inflammatory and inflammatory 
lesions of 12.3±7.7 and 9.1±4.5, respectively. More 
specifically, the percentage reduction of lesions was 
greater in men than in women, with a mean reduc-
tion of non-inflammatory lesions of 50.7±17.4% in 
men and 38.9±18.2% in women, while the percentage 
reduction of inflammatory lesions was 67.9±18.3% in 
men and 53.3±20.6% in women (Table 4). 
Patient satisfaction with treatment was positive, 
as shown in Figure 6, considering inflammatory le-
sions and minimal overall dropout rates (only four 
patients discontinued treatment).
In an efficacy study, combination therapy with 
benzoyl peroxide and topical antibiotics (e.g., eryth-
romycin) was found to be more effective and better 
tolerated than the gel vehicle (16). The same results 
obtained by Gupta et al. verified the efficacy of (5%) 
benzoyl peroxide-erythromycin (3%) treatment in 
acne vulgaris, showing significant reductions in pap-
ules, pustules and comedones. In addition, the 5% 
benzoyl peroxide-erythromycin 3% combination 
Figure 6. Patient satisfaction with treatment, including patients having completed the study and those who 
discontinued treatment (Ν=195).
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showed greater decrease in erythema and scaling 
when compared to 0.025% tretinoin-4% erythromy-
cin gel (17). The combination of 5% benzoyl peroxide 
and erythromycin 3% was also found more effica-
cious when compared with topical clindamycin or a 
combination of 4% erythromycin-zinc 1.2% as topical 
solution (18,19).
Similar efficacies were, however, observed be-
tween 5% benzoyl peroxide-erythromycin 3%, 5% 
benzoyl peroxide-clindamycin 1%, and 5% and 0.1% 
isotretinoin-erythromycin 4% for the treatment of 
mild to moderate acne vulgaris, showing improve-
ment in inflammatory lesions and a lower adverse 
event profile in case of 5% benzoyl peroxide-erythro-
mycin 3% (22,23).
ConClUSIon
The findings of this study confirmed the use of 5% 
benzoyl peroxide-erythromycin 3% topical gel to be 
efficient in the treatment of inflammatory acne, with 
satisfactory patient compliance and tolerance. This 
combination topical gel provides a safe alternative to 
topical treatment and systemic antibiotics, reducing 
the incidences of P. acnes resistance (24).
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